COPD-X Stepwise Management Navigator — Stable COPD Inhaler Pathway (Australia)

Home›Clinicians
🫁
COPD-X Stepwise Management Navigator

Answer a few questions about a stable COPD patient's current therapy and history — see where they sit on the COPD-X stepped-care pathway and what the guideline says about the next step. Educational tool reflecting the COPD-X Plan; not a prescribing aid.

🇦🇺 AustraliaCOPD-X Plan (LFA / TSANZ)
📋 Source: COPD-X Plan — Stepwise Management of Stable COPD (Lung Foundation Australia & Thoracic Society of Australia and New Zealand). This tool restates the published stepped-care pathway for general practice education. It does not account for individual patient factors, contraindications, comorbidities or PBS authority criteria — clinical decisions remain entirely with the treating clinician. Not medical advice.
1. What inhaled therapy is the patient currently on?
2. Despite current therapy, does the patient still have significant symptoms (breathlessness, exercise limitation)?
3. Exacerbations in the past 12 months?
4. Blood eosinophil count (most recent)?
COPD-X notes ICS is more likely to benefit patients with higher eosinophil counts and a history of exacerbations. Eosinophils <150 predict little ICS benefit; ≥300 predict greater benefit.
✅ For every COPD patient — at every step
The COPD-X Plan emphasises these run alongside all pharmacological steps:
  • Smoking cessation — the single most important intervention
  • Pulmonary rehabilitation — refer if symptomatic (centre-based, home-based, or telerehab)
  • Regular physical activity and exercise
  • Vaccinations — influenza, pneumococcal (Capvaxive from 1 July 2026), COVID-19, RSV
  • Inhaler technique — check and re-check at every visit; device errors are common
  • Written COPD action plan for exacerbations
  • Review comorbidities — cardiovascular disease, anxiety/depression, osteoporosis

Notes on the pathway

When does COPD-X suggest adding ICS?

ICS (as part of triple therapy) is considered for patients who continue to have exacerbations despite optimised LAMA/LABA, particularly where blood eosinophils are elevated. The COPD-X Plan notes:

  • Eosinophils <150 cells/µL: little benefit from ICS predicted
  • Eosinophils ≥300 cells/µL: greater benefit from ICS-containing therapy predicted
  • A documented history of ≥2 moderate or ≥1 severe exacerbation strengthens the case for ICS

ICS use must be balanced against risks (pneumonia, local effects). Review the full COPD-X section O4.2.1.

SABA + LAMA — what's the safety warning?

The Stepwise Management chart carries a safety warning about concomitant use of a short-acting muscarinic antagonist (SAMA, e.g. ipratropium) with a long-acting muscarinic antagonist (LAMA). These should not be used together — both act on the same receptor and combining them increases anticholinergic load without added benefit.

If a patient is on a LAMA (or LAMA-containing combination), the appropriate reliever is a short-acting beta2-agonist (SABA, e.g. salbutamol), not ipratropium or a SABA/SAMA combination.

Single inhaler vs multiple inhalers?

Where possible, COPD-X and international guidelines favour combining therapy into a single inhaler to improve adherence and reduce device-handling errors. Fixed-dose triple-therapy inhalers are available and PBS-subsidised for eligible patients.

Minimising the number of different device types a patient uses also reduces technique errors — the inhaler device chart helps match devices.

What about confirming the diagnosis first?

This pathway assumes a confirmed COPD diagnosis. COPD-X requires spirometry showing persistent airflow limitation (post-bronchodilator FEV1/FVC < 0.7) for diagnosis. If the diagnosis isn't confirmed on spirometry, that's the priority before escalating inhaled therapy.

Also consider whether features suggest asthma-COPD overlap — that changes the ICS calculus (asthma features favour earlier ICS).

Why isn't this a prescribing tool?

This navigator restates the published COPD-X stepped-care pathway for educational reference. It deliberately does not name specific brands, doses, or tell you what to prescribe for an individual — because real prescribing depends on contraindications, comorbidities, renal/cardiac status, prior intolerances, PBS authority criteria, patient preference, and inhaler technique, none of which a flowchart can assess. Use it to orient, then apply your own clinical judgement and the full guideline.

You might also like

🗓️
Patient Recall Card
Spirometry review, vaccinations, regular COPD review — generate a patient reminder card.
💉
Free Vaccine Eligibility Checker
COPD patients qualify for free pneumococcal, flu, RSV. Check eligibility.
🚭
Smoking Cost Calculator
A motivational tool for smoking cessation conversations.
🌱
Smoking & Vaping Cessation Guide
Step C of COPD-X in full: brief intervention, billing reality, pharmacotherapy comparison.